A 2025 meta-analysis in non–small-cell lung cancer (NSCLC) indicates glucocorticoid administration is significantly associated with worse progression-free survival (PFS) and overall survival (OS) for patients on ICIs. WJAMS. 2025;2(11):1-3. doi:10.65336/WJAMS.2025.21101